Angina pectoris

There are 317 papers on angina pectoris in aging research: 28 trials and 261 observational studies in people, 15 reviews. The newest story, Nov 9, 2026: “Cancer survivors with obesity had more cardiovascular disease”.

Disease

317 papers study it59 more mention it55 findings

MeSH

40 new papers in 30 daysSee all 376 papers on angina pectoris

At a glance

Angina pectoris is associated with myocardial infarction, coronary death and major adverse cardiac events in human cohorts. Phenotypic age acceleration is linked with higher angina risk, while faster gait is linked with lower risk. Human trials report reduced angina with coenzyme Q10 after acute myocardial infarction and with rosuvastatin at 10 versus 5 mg/day in unstable angina.

55 findings in 41 papers from 1998 to 2026, 12 of them since May 2026

“TSMR results indicated that MUFAs were associated with angina (OR=1.012, 95%CI:1.010-1.015)”
High Serum Monounsaturated Fatty Acids Levels May Increase Risk of Cardiovascular Disease: A Mendelian Randomization StudyIranian journal of medical sciences2026doi:10.30476/ijms.2026.107801.4239
  • Human trial28
  • Humans261
  • In silico9

Interventions

5

Ranolazine

downin humans1

1 study
  1. Ranolazine decreases angina pectoris in humans (hypertrophic cardiomyopathy).

    “Ranolazine consistently reduced angina and ventricular ectopy but did not increase peak VO2.”

    Reviewhypertrophic cardiomyopathy

    Metabolic Modulation in Hypertrophic Cardiomyopathy: A Systematic Review of Clinical and Observational Evidence

    European cardiology

More on Ranolazine

Rosuvastatin

downin humans1

1 study
  1. Rosuvastatin decreases angina pectoris in humans (unstable angina pectoris).

    “Group B was superior to group A in the onset times of myocardial ischemia and angina pectoris, the total duration of myocardial ischemia”

    Human trialunstable angina pectorisoral10 mg/day vs 5 mg/dayn = 106

    Effect of various doses of rosuvastatin in the treatment of elderly patients with unstable angina pectoris

    American journal of translational research

More on Rosuvastatin

Insulin

no changein humans1OR 1.1

1 study
  1. Insulin was not clearly linked with angina pectoris in humans (sex-stratified Mendelian randomization, women) (OR 1.10 (95% CI 0.38 to 3.18)).

    “angina OR 1.10, 95% CI 0.38 to 3.18”

    Humanssex-stratified Mendelian randomization, womengenetically predictedper pmol/L higher insulinfemales

    Sex-specific Mendelian randomization study of genetically predicted insulin and cardiovascular events in the UK Biobank

    Communications biology

More on Insulin

Testosterone

downin humans1

1 study
  1. Testosterone decreases angina pectoris in humans.

    “Testosterone decreases angina”

    Reviewmales

    Testosterone replacement therapy and cardiovascular risk factors modification

    The aging male : the official journal of the International Society for the Study of the Aging Male

More on Testosterone

Coenzyme Q10

downin humans1

1 study
  1. Coenzyme Q10 decreases angina pectoris in humans (patients with acute myocardial infarction) (9.5 vs. 28.1, P < 0.05).

    “angina pectoris (9.5 vs. 28.1), total arrhythmias (9.5% vs. 25.3%), and poor left ventricular function (8.2% vs. 22.5%) were significantly (P < 0.05) reduced in the coenzyme Q group than placebo group”

    Human trialpatients with acute myocardial infarctionoral120 mg/d28 days

    Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction

    Cardiovascular drugs and therapy

More on Coenzyme Q10

Effects

1

ADL disability

mediatesin humans1

1 study
  1. Angina pectoris is linked with ADL disability in humans (association between DAO and ADL disability) (7.7% mediated).

    “angina (7.7%) were significant mediators in the association between DAO and ADL disability”

    Humansassociation between DAO and ADL disabilityn = 20,198

    Dynapenic abdominal obesity and activities of daily living disability among older adults residing in low- and middle-income countries

    Aging clinical and experimental research

Associations

46

Major adverse cardiac events

upin humans2HR 2.34

2 studies
  1. Angina pectoris is associated with major adverse cardiac events in humans (Multivariable-adjusted association in a general population) (Adjusted HR 2.34, 95% CI 1.73-3.16).

    “Similar associations were observed for MACE (adjusted HR, 2.34; 95% CI, 1.73-3.16).”

    HumansMultivariable-adjusted association in a general populationMedian follow-up of 7.7 yearsBothsn = 24,176

    Importance of Angina Pectoris by Coronary Artery Disease Severity

    JAMA network open

  2. Angina pectoris predicts major adverse cardiac events in humans (Adjusted HR 2.34, 95% CI 1.73–3.16).

    “Similar patterns were observed for MACE (adjusted HR 2.34, 95% CI 1.73–3.16).”

    HumansMultivariable-adjusted association; participants without prior myocardial infarction, heart failure, or coronary revascularizationMedian follow-up of 7.7 years

    Long-term prognosis of angina pectoris in a general population – insights from the SCAPIS cohort

    ESC Congress 2026 abstract

Myocardial infarction or coronary death

upin humans2HR 1.65

2 studies
  1. Angina pectoris is associated with myocardial infarction or coronary death in humans (Multivariable-adjusted association in a general population) (Adjusted HR 1.65, 95% CI 1.04-2.63).

    “After multivariable adjustment, angina remained independently associated with the primary outcome (HR, 1.65; 95% CI, 1.04-2.63).”

    HumansMultivariable-adjusted association in a general populationMedian follow-up of 7.7 yearsBothsn = 24,176

    Importance of Angina Pectoris by Coronary Artery Disease Severity

    JAMA network open

  2. Angina pectoris predicts myocardial infarction or coronary death in humans (Adjusted HR 1.65, 95% CI 1.04–2.63).

    “After multivariable adjustment, the association remained significant (HR 1.65, 95% CI 1.04–2.63).”

    HumansMultivariable-adjusted association; participants without prior myocardial infarction, heart failure, or coronary revascularizationMedian follow-up of 7.7 years

    Long-term prognosis of angina pectoris in a general population – insights from the SCAPIS cohort

    ESC Congress 2026 abstract

SGLT2 inhibitors

downin humans1downin silico1HR 0.601

2 studies
  1. SGLT2 inhibitors are associated with angina pectoris in humans (moderate-to-severe plaque psoriasis receiving biologic therapy) (HR 0.601; 95% CI 0.404–0.894).

    “angina pectoris (HR, 0.601; 95%CI, 0.404-0.894)”

    Humansmoderate-to-severe plaque psoriasis receiving biologic therapy

    SGLT2 inhibitors and cardiovascular outcomes in patients with moderate-to-severe psoriasis receiving biologic therapy: A propensity score-matched cohort study

    Actas dermo-sifiliograficas

  2. SGLT2 inhibitors lower the risk of angina pectoris in silico (two-sample Mendelian randomization) (OR = 0.28, 95% CI: 0.11-0.70).

    “SGLT2 inhibition was associated with a significantly reduced risk of angina pectoris (odds ratio [OR] = 0.28, 95% confidence interval [CI]: 0.11-0.70, P = .007).”

    In silicotwo-sample Mendelian randomization

    Deciphering the interplay between SGLT2 inhibition, CCL4, and angina pectoris: A Mendelian randomization study

    Medicine

More on SGLT2 inhibitors

Dapagliflozin

downin humans1

1 study
  1. Dapagliflozin is associated with angina pectoris in humans (Diabetes with stable angina; improvement observed in both glycemic response groups) (CCS improvement in 49.1% of GR and 42.2% of NGR; mean CCS 1.85 to 1.18 and 2.05 to 1.33, respectively).

    “Dapagliflozin was associated with significant improvement in angina pectoris regardless of glycemic response or ventricular function.”

    HumansDiabetes with stable angina; improvement observed in both glycemic response groups10 mg/dayMedian 6 months53,1% malesn = 157

    Pleiotropic Effects of Dapagliflozin on Angina Pectoris: A Retrospective Analysis

    AHA Scientific Sessions 2026 abstract

More on Dapagliflozin

Diabetes mellitus and obesity co-occurrence

upin humans1

1 study
  1. diabetes mellitus and obesity co-occurrence is associated with angina pectoris in humans (Co-occurring diabetes mellitus and obesity; synergy beyond additive risk) (RERI 2.38; p=0.013).

    “DM+OB for CHD (RERI 1.55, p=0.007) and Angina (RERI 2.38, p=0.013)”

    HumansCo-occurring diabetes mellitus and obesity; synergy beyond additive riskn = 10,927

    Clustering of Vascular Risk Factors and Cardiovascular Disease Outcomes in U.S. Adults: A Cross-Sectional Analysis of NHANES 2013-2018

    AHA Scientific Sessions 2026 abstract

Smoking and obesity co-occurrence

upin humans1

1 study
  1. smoking and obesity co-occurrence is associated with angina pectoris in humans (Co-occurring smoking and obesity; synergy beyond additive risk) (RERI 1.99; p=0.028).

    “SMK+OB for Angina (RERI 1.99, p=0.028)”

    HumansCo-occurring smoking and obesity; synergy beyond additive riskn = 10,927

    Clustering of Vascular Risk Factors and Cardiovascular Disease Outcomes in U.S. Adults: A Cross-Sectional Analysis of NHANES 2013-2018

    AHA Scientific Sessions 2026 abstract

Smoking and hypertension co-occurrence

upin humans1

1 study
  1. smoking and hypertension co-occurrence is associated with angina pectoris in humans (Co-occurring smoking and hypertension; synergy beyond additive risk) (RERI 3.51; p=0.028).

    “SMK+HTN for CHD (RERI 1.92, p=0.035), Angina (RERI 3.51, p=0.028), and Stroke (RERI 2.25, p=0.038)”

    HumansCo-occurring smoking and hypertension; synergy beyond additive riskn = 10,927

    Clustering of Vascular Risk Factors and Cardiovascular Disease Outcomes in U.S. Adults: A Cross-Sectional Analysis of NHANES 2013-2018

    AHA Scientific Sessions 2026 abstract

Phenotypic Age Acceleration

upin humans1HR 1.01

1 study
  1. Phenotypic Age Acceleration is associated with angina pectoris in humans (HR 1.01, 95% CI 1.01–1.02 per 1-year increase).

    “angina (HR=1.01; 95%CI: 1.01,1.02)”

    HumansPer 1-year increaseMedian follow-up of 13.7 years46.8% malesn = 319,256

    Phenotypic age acceleration is associated with higher long-term cardiovascular and mortality risk: evidence from 319,256 UK Biobank participants

    ESC Congress 2026 abstract

More on Phenotypic Age Acceleration

Obstructive sleep apnea

upin humans1

1 study
  1. Obstructive sleep apnea is linked with a higher risk of angina pectoris in severe obesity with high waist circumference group.

    “OSA HR / Control HR was significantly higher for angina in the severe obesity with high waist circumference (HWC) group.”

    Humansin severe obesity with high waist circumference group

    Long-Term Cardiovascular Outcomes of Obstructive Sleep Apnea by Adiposity Phenotype: A Korean Nationwide Cohort Study

    Research SquarePreprint

More on Obstructive sleep apnea

Osteoporosis

upin humans1HR 1.621

1 study
  1. Angina pectoris is linked with a higher risk of osteoporosis in humans (fully adjusted time-dependent Cox model) (HR = 1.621, 95% CI: 1.081-2.430).

    “In the fully adjusted model, incident angina increased the risk of OP (HR = 1.621, 95% CI: 1.081-2.430, P = 0.02).”

    Humansfully adjusted time-dependent Cox modeln = 6,509

    Investigating the association between angina and osteoporosis: a 20-year longitudinal cohort study of ELSA

    BMC public health

More on Osteoporosis

All 46

Trial sponsors

Funding

2 grants since 2021

National Heart, Lung, and Blood Institute$486KJapan Society for the Promotion of Science¥4.2M

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 5Jan 2026: 13Feb 2026: 24Mar 2026: 19Apr 2026: 4May 2026: 6Jun 2026: 6Jul 2026: 6Aug 2026: 11Sep 2026: 8Oct 2026: 26Nov 2026: 19147 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Cancer survivors with obesity had more cardiovascular disease

Cardiovascular conditions affected 28.2% of cancer survivors with obesity, versus 15.6% of adults with obesity alone, despite lower levels of an inflammation marker.Cardiovascular conditions affected 28.2% of cancer survivors with obesity, versus 15.6% of adults with obesity alone, despite lower levels of an inflammation marker.

Cross-sectional · 325 peopleMechanisms
AHA Scientific Sessions 2026 Abstract

High social disadvantage linked to heart risk like mild artery calcium

Cardiovascular event rates were 3.77 per 1,000 person-years with high social disadvantage and no artery calcium, versus 3.12 with mild calcium and high disadvantage.Cardiovascular event rates were 3.77 per 1,000 person-years with high social disadvantage and no artery calcium, versus 3.12 with mild calcium and high disadvantage.

Cohort · 2,901 peoplePopulations

See all 376 papers on angina pectoris